StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a research report released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on TRVN. JMP Securities reaffirmed a market outperform rating and set a $2.00 price target on shares […]
StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a research report released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on TRVN. JMP Securities reaffirmed a market outperform rating and set a $2.00 price target on shares […]
Trevena, Inc. (NASDAQ:TRVN – Get Rating) saw a large growth in short interest in May. As of May 15th, there was short interest totalling 752,700 shares, a growth of 341.2% from the April 30th total of 170,600 shares. Based on an average trading volume of 2,500,000 shares, the short-interest ratio is currently 0.3 days. Approximately […]
Trevena, Inc. (NASDAQ:TRVN – Get Rating) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 752,700 shares, an increase of 341.2% from the April 30th total of 170,600 shares. Currently, 7.1% of the shares of the company are short sold. Based on an […]
StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a research report report published on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. TRVN has been the subject of a number of other reports. JMP Securities reiterated a market outperform rating and set a $2.00 price target […]